%0 Journal Article %A Samuel Clifford %A Pauline Waight %A Jada Hackman %A Stephane Hué %A Charlotte M Gower %A Freja CM Kirsebom %A Catriona Skarnes %A Louise Letley %A Jamie Lopez Bernal %A Nick Andrews %A Stefan Flasche %A Elizabeth Miller %T Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England %D 2021 %R 10.1101/2021.11.24.21266401 %J medRxiv %P 2021.11.24.21266401 %X Background The ability of SARS-CoV-2 vaccines to protect against infection and onward transmission determines whether immunisation can control global circulation. We estimated effectiveness of BNT162b2 and ChAdOx1 vaccines against acquisition and transmission of the Alpha and Delta variants in a prospective household study in England.Methods Adult index cases in the community and their household contacts took oral-nasal swabs on days 1, 3 and 7 after enrolment. Swabs were tested by RT-qPCR with genomic sequencing conducted on a subset. We used Bayesian logistic regression to infer vaccine effectiveness against acquisition and transmission, adjusted for age, vaccination history and variant.Findings Between 2 February 2021 and 10 September 2021 213 index cases and 312 contacts were followed up. After excluding households lacking genomic proximity (N=2) or with unlikely serial intervals (N=16), 195 households with 278 contacts remained of whom 113 (41%) became PCR positive. Delta lineages had 1.64 times the risk (95% Credible Interval: 1.15 – 2.44) of transmission than Alpha; contacts older than 18 years were 1.19 times (1.04 - 1.52) more likely to acquire infection than children. Effectiveness of two doses of BNT162b2 against transmission of Delta was 31% (−3%, 61%) and 42% (14%, 69%) for ChAdOx1, similar to their effectiveness for Alpha. Protection against infection with Alpha was higher than for Delta, 71% (12%,95%) vs 24% (−2%, 64%) respectively for BNT162b2 and 26% (−39%, 73%) vs 14% (−5%, 46%) respectively for ChAdOx1.Interpretation BNT162b2 and ChAdOx1 reduce transmission of the Delta variant from breakthrough infections in the household setting though their protection against infection is low.Funding This study was funded by the UK Health Security Agency (formerly Public Health England) as part of the COVID-19 response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the UK Health Security Agency (formerly Public Health England) (an executive agency of the Department of Health) as part of the COVID-19 response. Samuel Clifford is funded by the UK Medical Research Council (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics). Samuel Clifford and Stefan Flasche are funded by a Sir Henry Dale Fellowship funded by the Wellcome Trust and the Royal Society (208812/Z/17/Z). Jada Hackman is funded by the Nagasaki University-London School of Hygiene and Tropical Medicine Doctoral Programme under the WISE scheme. EM receives support from the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with the UKHSA (Grant Reference NIHR200929).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UKHSA Research Ethics and Governance Group gave approval for this work as part of the portfolio of the UKHSA's enhanced surveillance activities in response to the COVID-19 pandemicI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data necessary to replicate results is available from the authors on request, subject to a data sharing agreement. https://github.com/cmmid/hhSAR %U https://www.medrxiv.org/content/medrxiv/early/2021/11/25/2021.11.24.21266401.full.pdf